» Articles » PMID: 37894644

Peptides As Therapeutic Agents: Challenges and Opportunities in the Green Transition Era

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2023 Oct 28
PMID 37894644
Authors
Affiliations
Soon will be listed here.
Abstract

Peptides are at the cutting edge of contemporary research for new potent, selective, and safe therapeutical agents. Their rise has reshaped the pharmaceutical landscape, providing solutions to challenges that traditional small molecules often cannot address. A wide variety of natural and modified peptides have been obtained and studied, and many others are advancing in clinical trials, covering multiple therapeutic areas. As the demand for peptide-based therapies grows, so does the need for sustainable and environmentally friendly synthesis methods. Traditional peptide synthesis, while effective, often involves environmentally draining processes, generating significant waste and consuming vast resources. The integration of green chemistry offers sustainable alternatives, prioritizing eco-friendly processes, waste reduction, and energy conservation. This review delves into the transformative potential of applying green chemistry principles to peptide synthesis by discussing relevant examples of the application of such approaches to the production of active pharmaceutical ingredients (APIs) with a peptide structure and how these efforts are critical for an effective green transition era in the pharmaceutical field.

Citing Articles

Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model.

Nguyen C, Vu T, Nguyen M, Tran-Nguyen T, Huynh C, Ha Q Cancer Immunol Immunother. 2025; 74(4):145.

PMID: 40072566 DOI: 10.1007/s00262-025-03992-7.


and toxicity assessment of the antitumoral peptide GK-1.

Sifontes-Rodriguez S, Hernandez-Aceves J, Salas-Garrido C, Rocha D, Perez-Osorio I, Villalobos N Toxicol Rep. 2025; 14:101962.

PMID: 40034548 PMC: 11875144. DOI: 10.1016/j.toxrep.2025.101962.


Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins.

Elsayed Y, Kuhl T, Imhof D J Pept Sci. 2025; 31(3):e70001.

PMID: 39921384 PMC: 11806371. DOI: 10.1002/psc.70001.


Prediction of hemolytic peptides and their hemolytic concentration.

Rathore A, Kumar N, Choudhury S, Mehta N, Raghava G Commun Biol. 2025; 8(1):176.

PMID: 39905233 PMC: 11794569. DOI: 10.1038/s42003-025-07615-w.


Evaluation of Structure Prediction and Molecular Docking Tools for Therapeutic Peptides in Clinical Use and Trials Targeting Coronary Artery Disease.

Alotaiq N, Dermawan D Int J Mol Sci. 2025; 26(2).

PMID: 39859178 PMC: 11765240. DOI: 10.3390/ijms26020462.


References
1.
Al Musaimi O, Al Shaer D, Albericio F, de la Torre B . 2022 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel). 2023; 16(3). PMC: 10056021. DOI: 10.3390/ph16030336. View

2.
Miller R, Tadagavadi R, Ramesh G, Reeves W . Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2011; 2(11):2490-518. PMC: 3153174. DOI: 10.3390/toxins2112490. View

3.
Varela Y, Vanegas Murcia M, Patarroyo M . Synthetic Evaluation of Standard and Microwave-Assisted Solid Phase Peptide Synthesis of a Long Chimeric Peptide Derived from Four Proteins. Molecules. 2018; 23(11). PMC: 6278645. DOI: 10.3390/molecules23112877. View

4.
Gentilucci L, Tolomelli A, Squassabia F . Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem. 2006; 13(20):2449-66. DOI: 10.2174/092986706777935041. View

5.
Suematsu Y, Kawachi E, Idemoto Y, Matsuo Y, Kuwano T, Kitajima K . Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide. Int J Cardiol. 2019; 297:111-117. DOI: 10.1016/j.ijcard.2019.08.043. View